Heron Therapeutics 3Q 2026: Revenue $35.25M, EPS ($0.03) — 10-Q Summary
Heron Therapeutics reported 3Q 2026 revenue of $35.25M, down 7.8% YoY, with net loss narrowing to $5.01M. Acute care sales rose 22.5%, but oncology sales fell 22.2% due to competition. The company plans to sell assets to CorMedix, pending approval.
How this was made
The 30-second read
Why it matters
The narrowed loss and higher gross margin suggest operational improvements, but revenue contraction and oncology weakness keep upside limited.
Market read
Earnings release for a micro‑cap biotech; modest trading interest due to loss narrowing and upcoming asset sale.
What to watch
The pending asset sale to CorMedix and the CMS J‑code for APONVIE may provide longer‑term upside not reflected in the immediate numbers.
Background
Heron Therapeutics (HRTX) is a specialty biotech focused on acute‑care and oncology products. The 10‑Q filing provides the latest quarterly financial snapshot.
Ticker impact
Heron Therapeutics filed its 10‑Q reporting Q3 revenue of $35.25M and a narrowed net loss of $5.01M, the first public disclosure of these figures.
likely slight upside as the market prices in the narrowed loss and improved margin.
Revenue fell 7.8% YoY, but gross margin improved to 74.6% and operating expenses were cut, which may support a modest price gain.
Market effects
The acute‑care segment shows growth, while oncology sales remain pressured, indicating mixed signals for the broader biotech sector.
Limited to U.S. small‑cap biotech investors.
Low, as the company is a micro‑cap with niche product lines.
Counterpoint
The revenue decline and loss, despite margin improvement, could signal deeper demand weakness, prompting a short bias.
Key entities
- companyHeron Therapeutics
Issuer of the 10‑Q filing.
- companyCorMedix
Potential acquirer of Heron's assets.